LinkOPH

VIENNA — Five-year results of a study evaluating the safety and efficacy of bevacizumab in eyes with choroidal neovascularization secondary to pathologic myopia showed that the mean visual gain achieved at 2 years is not maintained. “We should now investigate the prognostic factors as we did with AMD,” Paolo Lanzetta, MD, said at the Advanced Retinal Therapy meeting. Phase 3 trials showed efficacy of Lucentis (ranibizumab, Novartis/Genentech) and Eylea (aflibercept, Bayer HealthCare/Regeneron) in inducing significant improvement in best corrected visual acuity over a shorter study duration.

Read more →

VIENNA — Fifteen-year data from the Blue Mountains Eye Study confirmed Age-Related Eye Disease Study findings on risk factors for progression of age-related macular degeneration, according to one speaker. “Both studies found that large drusen and pigment changes are the most powerful predictive factors. Patients who have neither of these signs have a less than 1% risk of developing late AMD over 5 years. With both of them in both eyes, the risk is 50%,” Paul Mitchell, MD, said at the Advanced Retinal Therapy meeting here.

Read more →

Yawn! Streeeeeetch. That was some weekend in New Orleans, eh? What did you learn? I mean, besides what those beads are really for! As always, there was information to be gathered at the American Academy of Ophthalmology meeting that was both purely cli…

Read more →

VIENNA — Ultra-widefield retinal imaging is a viable option that may improve the efficiency of diagnostics for diabetic retinopathy and diabetic macular edema, according to one specialist. Standard methods for assessment and follow-up of DR and DME have included fluorescein angiography, fundus photography and optical coherence tomography. However, novel ultra-widefield (UWF) scanning laser technology (Optos) allows wide-angle visualization that includes peripheral areas of the retina.

Read more →